Cargando…

Treatment of Recurrent or Metastatic Uterine Adenosarcoma

PURPOSE: This study retrospectively evaluated overall survival (OS) by treatment of recurrent or metastatic uterine adenosarcoma including surgery, radiation, chemotherapy, and hormonal therapy and evaluated OS and progression-free survival (PFS) after 1st line systemic chemotherapy. METHODS: 78 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Nathenson, Michael J., Conley, Anthony P., Lin, Heather, Fleming, Nicole, Ravi, Vinod
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763139/
https://www.ncbi.nlm.nih.gov/pubmed/29445312
http://dx.doi.org/10.1155/2017/4680273
_version_ 1783291828615774208
author Nathenson, Michael J.
Conley, Anthony P.
Lin, Heather
Fleming, Nicole
Ravi, Vinod
author_facet Nathenson, Michael J.
Conley, Anthony P.
Lin, Heather
Fleming, Nicole
Ravi, Vinod
author_sort Nathenson, Michael J.
collection PubMed
description PURPOSE: This study retrospectively evaluated overall survival (OS) by treatment of recurrent or metastatic uterine adenosarcoma including surgery, radiation, chemotherapy, and hormonal therapy and evaluated OS and progression-free survival (PFS) after 1st line systemic chemotherapy. METHODS: 78 patients with recurrent or metastatic adenosarcoma comprised the study population. The Kaplan-Meier method was used to estimate OS and PFS. The log-rank test was performed to test the difference in survival between groups. RESULTS: Median OS from diagnosis of recurrent or metastatic disease was 1.8 yrs. OS was influenced by pathology on recurrence, p=0.035. Median OS differed by surgery for 1st recurrence 26.3 months versus 15.1 months. OS was not influenced by chemotherapy, p=0.58, palliative radiation, p=0.58, or hormonal therapy, p=0.15. The response rate (CR + PR) per RECIST 1.1 for chemotherapy was 31.2% for doxorubicin-based regimens and 14.3% for gemcitabine/docetaxel. OS since 1st line chemotherapy was not significantly different among chemotherapy regimens. However, the median PFS was superior for doxorubicin/ifosfamide (15.4 months) compared to gemcitabine/docetaxel (5.0 months), platinum-based regimens (5.7 mo), or other doxorubicin-based regimens (6.5 months). CONCLUSION: These results suggest that surgery is an important treatment modality for recurrent or metastatic uterine adenosarcoma, and the most effective chemotherapeutics are doxorubicin/ifosfamide and gemcitabine/docetaxel.
format Online
Article
Text
id pubmed-5763139
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-57631392018-02-14 Treatment of Recurrent or Metastatic Uterine Adenosarcoma Nathenson, Michael J. Conley, Anthony P. Lin, Heather Fleming, Nicole Ravi, Vinod Sarcoma Research Article PURPOSE: This study retrospectively evaluated overall survival (OS) by treatment of recurrent or metastatic uterine adenosarcoma including surgery, radiation, chemotherapy, and hormonal therapy and evaluated OS and progression-free survival (PFS) after 1st line systemic chemotherapy. METHODS: 78 patients with recurrent or metastatic adenosarcoma comprised the study population. The Kaplan-Meier method was used to estimate OS and PFS. The log-rank test was performed to test the difference in survival between groups. RESULTS: Median OS from diagnosis of recurrent or metastatic disease was 1.8 yrs. OS was influenced by pathology on recurrence, p=0.035. Median OS differed by surgery for 1st recurrence 26.3 months versus 15.1 months. OS was not influenced by chemotherapy, p=0.58, palliative radiation, p=0.58, or hormonal therapy, p=0.15. The response rate (CR + PR) per RECIST 1.1 for chemotherapy was 31.2% for doxorubicin-based regimens and 14.3% for gemcitabine/docetaxel. OS since 1st line chemotherapy was not significantly different among chemotherapy regimens. However, the median PFS was superior for doxorubicin/ifosfamide (15.4 months) compared to gemcitabine/docetaxel (5.0 months), platinum-based regimens (5.7 mo), or other doxorubicin-based regimens (6.5 months). CONCLUSION: These results suggest that surgery is an important treatment modality for recurrent or metastatic uterine adenosarcoma, and the most effective chemotherapeutics are doxorubicin/ifosfamide and gemcitabine/docetaxel. Hindawi 2017 2017-12-28 /pmc/articles/PMC5763139/ /pubmed/29445312 http://dx.doi.org/10.1155/2017/4680273 Text en Copyright © 2017 Michael J. Nathenson et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Nathenson, Michael J.
Conley, Anthony P.
Lin, Heather
Fleming, Nicole
Ravi, Vinod
Treatment of Recurrent or Metastatic Uterine Adenosarcoma
title Treatment of Recurrent or Metastatic Uterine Adenosarcoma
title_full Treatment of Recurrent or Metastatic Uterine Adenosarcoma
title_fullStr Treatment of Recurrent or Metastatic Uterine Adenosarcoma
title_full_unstemmed Treatment of Recurrent or Metastatic Uterine Adenosarcoma
title_short Treatment of Recurrent or Metastatic Uterine Adenosarcoma
title_sort treatment of recurrent or metastatic uterine adenosarcoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763139/
https://www.ncbi.nlm.nih.gov/pubmed/29445312
http://dx.doi.org/10.1155/2017/4680273
work_keys_str_mv AT nathensonmichaelj treatmentofrecurrentormetastaticuterineadenosarcoma
AT conleyanthonyp treatmentofrecurrentormetastaticuterineadenosarcoma
AT linheather treatmentofrecurrentormetastaticuterineadenosarcoma
AT flemingnicole treatmentofrecurrentormetastaticuterineadenosarcoma
AT ravivinod treatmentofrecurrentormetastaticuterineadenosarcoma